Sleep Initiation and Maintenance DisordersPhase 3NCT00756002
Safety and Efficacy Study of Ramelteon in Subjects With Chronic Insomnia
A Phase 3 study testing Ramelteon in people with Sleep Initiation and Maintenance Disorders, run by Takeda.
Trial summary
The purpose of this study is to determine the safety and efficacy of 4 mg of Ramelteon, once daily (QD), in subjects with chronic insomnia. Read more about this study
- Who is it for?
- Ages 18 to 64 years
- Conditions the study is for
- Sleep Initiation and Maintenance Disorders
- What is being tested?
- Ramelteon
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 259 participants
- Where
- No sites listed yet
- Study dates
- Aug 2007to Mar 2008
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 64 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- A female subject of childbearing potential who is sexually active agrees to use adequate contraception from Screening throughout the duration of the study.
- Has a body mass index between 18 and 34, inclusive.
- Based on sleep history, the subject has had chronic insomnia for at least 3 months, as defined by the following:
- The predominant complaint is difficulty initiating or maintaining sleep, or non-restorative sleep, for at least 3 months.
- The sleep disturbance (or associated daytime fatigue) causes clinically significant distress or impairment in social, occupational, or other important areas of functioning.
- The sleep disturbance does not occur exclusively during the course of narcolepsy, breathing-related sleep disorder, circadian rhythm sleep disorder, or parasomnia.
Show all 20Show fewer
- The disturbance does not occur exclusively during the course of another mental disorder (eg, major depressive disorder, generalized anxiety disorder, delirium).
- The disturbance is not due to the direct physiological effects of a substance or a general medical condition.
- Based on sleep history, the subject reports a history of subjective sleep latency ≥45 minutes and a subjective total sleep time ≤6.5 hours for at least 3 months.
- Based on sleep history, the subject's habitual bedtime is between 10:00 PM and 1:00 AM.
- On at least 3 of the first 5 nights of single blind run-in placebo treatment, the subject must have an subjective sleep latency of ≥45 minutes and a subjective total sleep time of <6.5 hours.
- The difference of the average subjective sleep latency from first 3 nights of data in the first week of single-blind run-in to the average of the last 3 nights of data in the first week of single-blind run-in must be ≤30 minutes.
- The difference of the average subjective sleep latency from first 3 nights of data in the first week of single-blind run-in to the average of the last 3 nights of data in the second week of single-blind run-in must be ≤30 minutes.
- The difference of the average subjective sleep latency from first 3 nights of data in the first week of single-blind run-in to the average of the last 3 nights of data in the third week of single-blind run-in must be ≤30 minutes.
- Is willing to have a fixed bedtime and agrees to go to bed within ± 30 minutes of the habitual bedtime during the entire study, exceptions will be allowed at weekends that are not within 2 days of a polysomnography visit.
- Has consistent access to a touch-tone phone and is willing to complete all telephone questionnaires within 60 minutes of wake time each morning throughout the entire duration of the study.
- Is willing to remain in bed for at least 6.5 hours each night during the entire study.
- Based on sleep history, the subject normally uses pharmacologic assistance to sleep 0 to 4 (maximum allowable) times per week in the last 3 months. Subjects must agree to discontinue the use of all sleep aids beginning 1 week prior to the first dose of single-blind study medication and throughout the entire duration of the study.
- The subject must complete the post-sleep questionnaire morning questionnaire on at least 5 of 7 mornings for all 3 weeks of single-blind run-in.
- Has a mean latency to persistent sleep of ≥20 minutes on 2 consecutive screening nights, with neither night less than 15 minutes, via polysomnography screening assessment during the single-blind placebo run-in period.
Who cannot join
- Has a known hypersensitivity to ramelteon or related compounds, including melatonin.
- Has participated in a study involving ramelteon within 6 months of initial Screening Visit.
- Has participated in any other investigational study and/or taken any investigational drug within 30 days or 5 half-lives (whichever is longer) prior to the first night of single-blind study medication.
- Has sleep schedule changes required by employment (eg, shift worker) within 3 months prior to the first night of single-blind study medication, or has flown across greater than 3 time zones within 7 days prior to Screening.
- Has participated in a weight loss program or has substantially altered his or her exercise routine within 30 days prior to the first night of single-blind study medication.
- Has ever had a history of seizures, sleep apnea, restless leg syndrome, periodic leg movements during sleep, chronic obstructive pulmonary disease, fibromyalgia, schizophrenia, bipolar disorder, mental retardation or a cognitive disorder.
Show all 43Show fewer
- Has a history of psychiatric disorder (including anxiety or depression) within the past 12 months.
- Has a history of drug addiction or alcohol abuse and/or regularly consumes 4 or more alcoholic drinks per day within the past 12 months, as defined in Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Revised.
- Has a current significant neurological (including cognitive and psychiatric disorders), hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematological, or metabolic disease, unless currently controlled and stable with protocol-allowed medication 30 days prior to the first night of single blind study medication.
- The subject uses tobacco products (including nicotine gum and patch) during nightly awakenings.
- The subject has any clinically important abnormal finding as determined by a medical history, physical examination, electrocardiogram, or clinical laboratory tests, as determined by the investigator.
- The subject is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:
- Anxiolytics
- Central nervous system active drugs (including herbal)
- Hypnotics
- Narcotic analgesics
- Antidepressants
- Beta-blockers
- Anticonvulsants
- Systemic steroids
- Sedating H1 antihistamines
- Respiratory stimulants
- Muscle relaxants
- Sedatives
- Antipsychotics
- Sedating decongestants
- Kava-kava
- St. John's wort
- Ginkgo biloba
- Over-the counter and prescription stimulants, diet aids and sleep aids
- Drugs that are known or are suspected to significantly inhibit CYP450
- Melatonin
- Has a positive urine drug screen for an illegal substance at the initial Screening Visit.
- Has a positive urine drug screen at polysomnography screening or a positive alcohol breathalyzer test at polysomnography screening or randomization.
- Exhibits a placebo response during the single-blind placebo run-in period. A placebo response is defined as having:
- a difference in average subjective sleep latency >30 minutes from first 3 nights of data in the first week of single-blind run-in to the average of the last 3 nights of data in the first week of single-blind run-in.
- a difference in average subjective sleep latency >30 minutes from first 3 nights of data in the first week of single-blind run-in to the average of the last 3 nights of data in the second week of single-blind run-in.
- a difference in average subjective sleep latency >30 minutes from first 3 nights of data in the first week of single-blind run-in to the average of the last 3 nights of data in the third week of single-blind run-in.
- Has periodic leg movements during sleep with arousal index (per hour of sleep) >10 as seen on polysomnography on the first night of polysomnography screening.
- Has any additional condition(s) that in the Investigator's opinion would:
- Affect sleep/wake function
- Prohibit the subject from completing the study
- Not be in the best interest of the subject to complete the study.
About this study
Official title: A Randomized, Double-Blind, Placebo-Controlled, Polysomnography Plus Outpatient Study to Determine the Safety and Efficacy of 4 mg Ramelteon in Adults With Chronic Insomnia
The purpose of this study is to determine the safety and efficacy of 4 mg of Ramelteon, once daily (QD), in subjects with chronic insomnia.
Read the detailed description
In the western world, there are several people affected by chronic insomnia. Numerous studies estimate that 30% to 40% of the general population is affected at some time in their lives with a form of insomnia that goes on for several months, and about one third of those are described as severely affected. Daytime symptoms of insomnia include tiredness, lack of energy, difficulty concentrating and irritability. Recent epidemiologic research focusing on the quality of life has identified significant insomnia-related morbidities that relate to work productivity, health care utilization, and risk of depression. Insomnia is associated with diminished work output, absenteeism, and greater rates of accidents.
Although normal control of the sleep-wake cycle is exerted by the suprachiasmatic nucleus via melatonin receptor subtype 1 and 2 (MT1 and MT2) receptors (melatonin receptor subtype), most current pharmacologic treatments for insomnia mainly involve GABAergic (gamma-aminobutyric acid) mechanisms. Most currently prescribed sleep agents are benzodiazepine receptor agonists, which induce sleep by binding to the benzodiazepine receptor site of the gamma-aminobutyric acid-A receptor complex. Gamma-aminobutyric acid is the major inhibitory transmitter in the central nervous system, and its receptors are distributed widely throughout the brain. In addition to sleep, benzodiazepine receptor agonists can cause a wide range of ancillary effects not directly related to sleep, depending on the precise subset of gamma-aminobutyric acid-A receptors activated. These include sedative, anxiolytic, muscle-relaxant, and amnesic effects. The risk of tolerance, dependence development, and abuse potential associated with the benzodiazepine receptor agonists also may reflect effects of these drugs on the gamma-aminobutyric acid-A receptor complex.
The sleep-wake cycle results from the interaction of circadian and homeostatic mechanisms. The homeostatic mechanism refers to the accumulation of sleep load during time awake; the organism falls asleep when the sleep load is high, and the reduction of sleep load during sleep results in waking.
A circadian rhythm is superimposed on the homeostatic mechanism. Circadian rhythms are controlled by the suprachiasmatic nucleus, which emits alerting signals; this signal is believed to be attenuated by melatonin, which is produced in response to darkness. It is believed that binding of melatonin to MT1 and MT2 receptors in the suprachiasmatic nucleus inhibits firing of specific neurons, and this is thought to attenuate the alerting signal, allowing the homeostatic mechanism to express itself and promote sleep.
An agent that is selective for the MT1 and MT2 receptors would be expected to be devoid of the ancillary effects of agents that act at the gamma-aminobutyric acid-A receptor complex. It would promote sleep by specifically targeting the alerting signal in the suprachiasmatic nucleus, allowing the homeostatic mechanism to produce sleep.
Ramelteon is under global development by Takeda Pharmaceuticals as a nonscheduled sleep agent for the treatment of difficulty with sleep initiation, and is marketed under the brand name of Rozerem™ in the United States. In vitro, ramelteon demonstrates affinity and selectivity for human melatonin MT1 and MT2 receptors compared to melatonin. It also demonstrates full agonist activity in cells expressing human MT1 or MT2 receptors relative to melatonin.
In the European Union, Takeda is seeking marketing approval for the long-term treatment of transient and chronic insomnia as characterized by difficulty with sleep onset. Because most of the European clinical studies to date have used the 8 mg dose, the aim of this study is to assess the safety and efficacy of 4mg of ramelteon in a larger number of adults with chronic insomnia.
Subjects participating in this study will be required to report to a sleep laboratory and have polysomnography recordings over two consecutive nights for three sittings during a five week period. The total duration of the study is approximately 10 weeks.
- Being tested
- Ramelteon, Placebo
- Keywords
- Chronic Insomnia, DIMS (Disorders of Initiating and Maintaining Sleep), Disorders of Initiating and Maintaining Sleep, Insomnia Disorder Sleep Initiation Dysfunction, Transient Insomnia, Drug Therapy, Sleep Disorders, Intrinsic
- Medical subject headings
- Sleep Initiation and Maintenance Disorders, Sleep Disorders, Intrinsic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RamelteonDrug
Also called Rozerem™, TAK-375
Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks.
PlaceboDrug
Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Ramelteon 4 mg QD | Experimental | Not described Receives: Drug: Ramelteon |
| Placebo QD | Placebo comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean Latency to Persistent Sleep Via Polysomnography (Nights 1-2).
Elapsed time from the beginning of the Polysomnography recording to the onset of the first 10 minutes of continuous sleep was measured over 2 nights and the average time to sleep was calculated.
Measured: Nights 1-2
Secondary outcomes (44)
Mean Latency to Persistent Sleep Via Polysomnography (Nights 15-16).
Elapsed time from the beginning of the Polysomnography recording to the onset of the first 10 minutes of continuous sleep was measured.
Measured: Nights 15-16
Mean Latency to Persistent Sleep Via Polysomnography (Nights 29-30).
Elapsed time from the beginning of the Polysomnography recording to the onset of the first 10 minutes of continuous sleep was measured.
Measured: Nights 29-30
Subjective Sleep Latency, Per Post-sleep Questionnaire (Nights 1-2).
Subjective sleep latency was collected by subjects answering a post-sleep questionnaire via an interactive voice response system (IVRS) following an overnight Polysomnography in the sleep lab.
Measured: Nights 1-2
Subjective Sleep Latency, Per Post-sleep Questionnaire (Nights 15-16).
Subjective sleep latency was collected by subjects answering a post-sleep questionnaire (via IVRS) following an overnight Polysomnography in the sleep lab.
Measured: Nights 15-16
Subjective Sleep Latency, Per Post-sleep Questionnaire (Nights 29-30).
Subjective sleep latency was collected by subjects answering a post-sleep questionnaire (via IVRS) following an overnight Polysomnography in the sleep lab.
Measured: Nights 29-30
Subjective Sleep Latency, Per Post-sleep Questionnaire (Week 2).
Subjects answered a post-sleep questionnaire via IVRS. The Subjective Sleep Latency weekly average was the mean of the daily Post-Sleep Questionnaire for the 7 nights prior to the corresponding Visit and predominantly contained data from the natural "home" setting.
Measured: Week 2
Subjective Sleep Latency, Per Post-sleep Questionnaire (Week 4).
Subjects answered a post-sleep questionnaire via IVRS. The Subjective Sleep Latency weekly average was the mean of the daily Post-Sleep Questionnaire for the 7 nights prior to the corresponding Visit and predominantly contained data from the natural "home" setting.
Measured: Week 4
Subjective Sleep Latency, Per Post-sleep Questionnaire (Week 5).
Subjects answered a post-sleep questionnaire via IVRS. The Subjective Sleep Latency weekly average was the mean of the daily Post-Sleep Questionnaire for the 7 nights prior to the corresponding Visit and predominantly contained data from the natural "home" setting.
Measured: Week 5
Total Sleep Time, Per Polysomnography (Nights 1-2).
All of the minutes of Stages 1, 2, 3/4 Non Rapid Eye-Movement (NREM) and Rapid-Eye-Movement (REM) sleep, as measured by Polysomnography, are summed to determine the Total Sleep Time.
Measured: Nights 1-2
Total Sleep Time, Per Polysomnography (Nights 15-16).
All of the minutes of Stages 1, 2, 3/4 NREM and REM sleep, as measured by Polysomnography, are summed to determine the Total Sleep Time.
Measured: Nights 15-16
Total Sleep Time, Per Polysomnography (Nights 29-30).
All of the minutes of Stages 1, 2, 3/4 NREM and REM sleep, as measured by Polysomnography, are summed to determine the Total Sleep Time.
Measured: Nights 29-30
Subjective Total Sleep Time, Per Post-sleep Questionnaire (Nights 1-2).
Subjects answered a Post-Sleep Questionnaire in the sleep lab the morning following overnight Polysomnography. Subjective Total Sleep Time measured the average of the 2 mornings after each overnight Polysomnography Visit.
Measured: Nights 1-2
Subjective Total Sleep Time, Per Post-sleep Questionnaire (Nights 15-16).
Subjects answered a Post-Sleep Questionnaire in the sleep lab the morning following overnight Polysomnography. Subjective Total Sleep Time measured the average of the 2 mornings after each overnight Polysomnography Visit.
Measured: Nights 15-16
Subjective Total Sleep Time, Per Post-sleep Questionnaire (Nights 29-30).
Subjects answered a Post-Sleep Questionnaire in the sleep lab the morning following overnight Polysomnography. Subjective Total Sleep Time measured the average of the 2 mornings after each overnight Polysomnography Visit.
Measured: Nights 29 -30
Subjective Total Sleep Time, Per Post-sleep Questionnaire (Week 2).
Subjects answered a Post-Sleep Questionnaire via IVRS. The Subjective Total Sleep Time weekly average was the mean of the daily Post-Sleep Questionnaire for the 7 nights prior to the corresponding Visit and predominantly contained data from the natural "home" setting.
Measured: Week 2
Subjective Total Sleep Time, Per Post-sleep Questionnaire (Week 4).
Subjects answered a Post-Sleep Questionnaire via IVRS. The Subjective Total Sleep Time weekly average was the mean of the daily Post-Sleep Questionnaire for the 7 nights prior to the corresponding Visit and predominantly contained data from the natural "home" setting.
Measured: Week 4
Subjective Total Sleep Time, Per Post-sleep Questionnaire (Week 5).
Subjects answered a Post-Sleep Questionnaire via IVRS. The Subjective Total Sleep Time weekly average was the mean of the daily Post-Sleep Questionnaire for the 7 nights prior to the corresponding Visit and predominantly contained data from the natural "home" setting.
Measured: Week 5
Sleep Efficiency, Per Polysomnography (Nights 1-2).
The total sleep time was divided by the total time in bed (ie, the number of minutes from the beginning of the Polysomnography recording to the end of the recording), multiplied by 100.
Measured: Nights 1-2
Sleep Efficiency, Per Polysomnography (Nights 15-16).
The total sleep time was divided by the total time in bed (ie, the number of minutes from the beginning of the Polysomnography recording to the end of the recording), multiplied by 100.
Measured: Nights 15-16
Sleep Efficiency, Per Polysomnography (Nights 29-30).
The Total Sleep Time was divided by the total time in bed (ie, the number of minutes from the beginning of the Polysomnography recording to the end of the recording), multiplied by 100.
Measured: Nights 29-30
Subjective Sleep Quality, Per Post-sleep Questionnaire (Nights 1-2).
Sleep quality obtained from the Post-Sleep Questionnaire performed in the sleep lab the morning following overnight Polysomnography. 7=Extremely Poor; 6=Very Poor; 5=Poor; 4=Fair; 3=Good; 2=Very Good; 1=Excellent.
Measured: Nights 1-2
Subjective Sleep Quality, Per Post-sleep Questionnaire (Nights 15-16).
Sleep quality obtained from the Post-Sleep Questionnaire performed in the sleep lab the morning following overnight Polysomnography. 7=Extremely Poor; 6=Very Poor; 5=Poor; 4=Fair; 3=Good; 2=Very Good; 1=Excellent.
Measured: Nights 15-16
Subjective Sleep Quality, Per Post-sleep Questionnaire (Nights 29-30).
Sleep quality obtained from the Post-Sleep Questionnaireperformed in the sleep lab the morning following overnight Polysomnography. 7=Extremely Poor; 6=Very Poor; 5=Poor; 4=Fair; 3=Good; 2=Very Good; 1=Excellent.
Measured: Nights 29-30
Subjective Sleep Quality, Per Post-sleep Questionnaire (Week 2).
The subjective sleep quality weekly average was the mean of the daily Post-Sleep Questionnaire for the 7 nights prior to the corresponding Visit and predominantly contained data from the natural "home" setting. 7=Extremely Poor; 6=Very Poor; 5=Poor; 4=Fair; 3=Good; 2=Very Good; 1=Excellent.
Measured: Week 2
Subjective Sleep Quality, Per Post-sleep Questionnaire (Week 4).
The subjective sleep quality weekly average was the mean of the daily Post-Sleep Questionnaire for the 7 nights prior to the corresponding Visit and predominantly contained data from the natural "home" setting. 7=Extremely Poor; 6=Very Poor; 5=Poor; 4=Fair; 3=Good; 2=Very Good; 1=Excellent.
Measured: Week 4
Subjective Sleep Quality, Per Post-sleep Questionnaire (Week 5).
The subjective sleep quality weekly average was the mean of the daily Post-Sleep Questionnaire for the 7 nights prior to the corresponding Visit and predominantly contained data from the natural "home" setting. 7=Extremely Poor; 6=Very Poor; 5=Poor; 4=Fair; 3=Good; 2=Very Good; 1=Excellent.
Measured: Week 5
Wake Time After Sleep Onset, Per Polysomnography (Nights 1-2).
The number of minutes in the Awake stage after the onset of persistent sleep to the end of the recording.
Measured: Nights 1-2
Wake Time After Sleep Onset, Per Polysomnography (Nights 15-16).
The number of minutes in the Awake stage after the onset of persistent sleep to the end of the recording.
Measured: Nights 15-16
Wake Time After Sleep Onset, Per Polysomnography (Nights 29-30).
The number of minutes in the Awake stage after the onset of persistent sleep to the end of the recording.
Measured: Nights 29-30
Subjective Wake Time After Sleep Onset, Per Post-sleep Questionnaire (Nights 1-2).
Subjective Wake Time After Sleep Onset obtained from the Post-Sleep Questionnaire performed in the sleep lab the morning following overnight Polysomnography.
Measured: Nights 1-2
Subjective Wake Time After Sleep Onset, Per Post-sleep Questionnaire (Nights 15-16).
Subjective Wake Time After Sleep Onset obtained from the Post-Sleep Questionnaire performed in the sleep lab the morning following overnight Polysomnography.
Measured: Nights 15-16
Subjective Wake Time After Sleep Onset, Per Post-sleep Questionnaire (Nights 29-30).
Subjective Wake Time After Sleep Onset obtained from the Post-Sleep Questionnaire performed in the sleep lab the morning following overnight Polysomnography.
Measured: Nights 29-30
Subjective Wake Time After Sleep Onset, Per Post-sleep Questionnaire (Week 2).
The Subjective Wake Time After Sleep Onset weekly average was the mean of the daily Post-Sleep Questionnaire for the 7 nights prior to the corresponding Visit and predominantly contained data from the natural "home" setting.
Measured: Week 2
Subjective Wake Time After Sleep Onset, Per Post-sleep Questionnaire (Week 4).
The Subjective Wake Time After Sleep Onset weekly average was the mean of the daily Post-Sleep Questionnaire for the 7 nights prior to the corresponding Visit and predominantly contained data from the natural "home" setting.
Measured: Week 4
Subjective Wake Time After Sleep Onset, Per Post-sleep Questionnaire (Week 5).
The Subjective Wake Time After Sleep Onset weekly average was the mean of the daily Post-Sleep Questionnaire for the 7 nights prior to the corresponding Visit and predominantly contained data from the natural "home" setting.
Measured: Week 5
Number of Awakenings After Persistent Sleep, Per Polysomnography (Nights 1-2).
Number of Awakenings is defined as the number of times after the onset of persistent sleep that there is a wake entry of at least 2 epochs in duration. Each entry must be separated by Stage 2, 3/4 NREM sleep or REM sleep in order to be counted.
Measured: Nights 1-2
Number of Awakenings After Persistent Sleep, Per Polysomnography (Nights 15-16).
Number of Awakenings is defined as the number of times after the onset of persistent sleep that there is a wake entry of at least 2 epochs in duration. Each entry must be separated by Stage 2, 3/4 NREM sleep or REM sleep in order to be counted.
Measured: Nights 15-16
Number of Awakenings After Persistent Sleep, Per Polysomnography (Nights 29-30).
Number of Awakenings is defined as the number of times after the onset of persistent sleep that there is a wake entry of at least 2 epochs in duration. Each entry must be separated by Stage 2, 3/4 NREM sleep or REM sleep in order to be counted.
Measured: Nights 29-30
Subjective Number of Awakenings, Per Post-sleep Questionnaire (Nights 1-2).
Subjective Number of Awakenings (the subjective measure of how many times the subject believes they awoke during the night) obtained from the Post-Sleep Questionnaire performed in the sleep lab the morning following overnight Polysomnography. The average of two nights' data is used for each subject at a visit.
Measured: Nights 1-2
Subjective Number of Awakenings, Per Post-sleep Questionnaire (Nights 15-16).
Subjective Number of Awakenings (the subjective measure of how many times the subject believes they awoke during the night) obtained from the Post-Sleep Questionnaire performed in the sleep lab the morning following overnight Polysomnography. The average of two nights' data is used for each subject at a visit.
Measured: Nights 15-16
Subjective Number of Awakenings, Per Post-sleep Questionnaire (Nights 29-30).
Subjective Number of Awakenings (the subjective measure of how many times the subject believes they awoke during the night) obtained from the Post-Sleep Questionnaire performed in the sleep lab the morning following overnight Polysomnography. The average of two nights' data is used for each subject at a visit.
Measured: Nights 29-30
Subjective Number of Awakenings, Per Post-sleep Questionnaire (Week 2).
The Subjective Number of Awakenings weekly average was the mean of the daily Post-Sleep Questionnaire for the 7 nights prior to the corresponding Visit and predominantly contained data from the natural "home" setting.
Measured: Week 2
Subjective Number of Awakenings, Per Post-sleep Questionnaire (Week 4).
The Subjective Number of Awakenings weekly average was the mean of the daily Post-Sleep Questionnaire for the 7 nights prior to the corresponding Visit and predominantly contained data from the natural "home" setting.
Measured: Week 4
Subjective Number of Awakenings, Per Post-sleep Questionnaire (Week 5).
The Subjective Number of Awakenings weekly average was the mean of the daily Post-Sleep Questionnaire for the 7 nights prior to the corresponding Visit and predominantly contained data from the natural "home" setting.
Measured: Week 5
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2008 (estimated)
- Study startAug 2007
- Primary completionMar 2008
- Study completionMar 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Sleep Initiation and Maintenance DisordersStudies of the same condition, open and under way.
- More trials run by TakedaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 259 participants (actual)
Sponsor and investigators
- Lead sponsor
- Takeda
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Medical Director Clinical Science, Study director, Takeda
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00756002
- Sponsor's protocol ID
- 01-06-TL-375-081
- Other IDs
- 2007-000403-15, U1111-1115-2084
- Status last verified
- May 2010
- First submitted
- 17 Sep 2008
- Last updated
- 2 Jun 2010
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Jun 2010. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Polysomnography Plus Outpatient Study to Determine the Safety and Efficacy of 4 mg Ramelteon in Adults With Chronic Insomnia
- ClinicalTrials.gov ID
- NCT00756002
- Acronym / sponsor ID
- 01-06-TL-375-081
- Keywords
- Chronic Insomnia, DIMS (Disorders of Initiating and Maintaining Sleep), Disorders of Initiating and Maintaining Sleep, Insomnia Disorder Sleep Initiation Dysfunction, Transient Insomnia, Drug Therapy, Sleep Disorders, Intrinsic
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 259 participants (actual)
- Lead sponsor
- TakedaIndustry (pharma, biotech, devices)
- Study start
- Aug 2007
- Primary completion
- Mar 2008 (actual)
- Study completion
- Mar 2008 (actual)
- First posted
- 19 Sep 2008 (estimated)
- Results
- Posted 5 Nov 2009
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine the safety and efficacy of 4 mg of Ramelteon, once daily (QD), in subjects with chronic insomnia.
Detailed description
In the western world, there are several people affected by chronic insomnia. Numerous studies estimate that 30% to 40% of the general population is affected at some time in their lives with a form of insomnia that goes on for several months, and about one third of those are described as severely affected. Daytime symptoms of insomnia include tiredness, lack of energy, difficulty concentrating and irritability. Recent epidemiologic research focusing on the quality of life has identified significant insomnia-related morbidities that relate to work productivity, health care utilization, and risk of depression. Insomnia is associated with diminished work output, absenteeism, and greater rates of accidents.
Although normal control of the sleep-wake cycle is exerted by the suprachiasmatic nucleus via melatonin receptor subtype 1 and 2 (MT1 and MT2) receptors (melatonin receptor subtype), most current pharmacologic treatments for insomnia mainly involve GABAergic (gamma-aminobutyric acid) mechanisms. Most currently prescribed sleep agents are benzodiazepine receptor agonists, which induce sleep by binding to the benzodiazepine receptor site of the gamma-aminobutyric acid-A receptor complex. Gamma-aminobutyric acid is the major inhibitory transmitter in the central nervous system, and its receptors are distributed widely throughout the brain. In addition to sleep, benzodiazepine receptor agonists can cause a wide range of ancillary effects not directly related to sleep, depending on the precise subset of gamma-aminobutyric acid-A receptors activated. These include sedative, anxiolytic, muscle-relaxant, and amnesic effects. The risk of tolerance, dependence development, and abuse potential associated with the benzodiazepine receptor agonists also may reflect effects of these drugs on the gamma-aminobutyric acid-A receptor complex.
The sleep-wake cycle results from the interaction of circadian and homeostatic mechanisms. The homeostatic mechanism refers to the accumulation of sleep load during time awake; the organism falls asleep when the sleep load is high, and the reduction of sleep load during sleep results in waking.
A circadian rhythm is superimposed on the homeostatic mechanism. Circadian rhythms are controlled by the suprachiasmatic nucleus, which emits alerting signals; this signal is believed to be attenuated by melatonin, which is produced in response to darkness. It is believed that binding of melatonin to MT1 and MT2 receptors in the suprachiasmatic nucleus inhibits firing of specific neurons, and this is thought to attenuate the alerting signal, allowing the homeostatic mechanism to express itself and promote sleep.
An agent that is selective for the MT1 and MT2 receptors would be expected to be devoid of the ancillary effects of agents that act at the gamma-aminobutyric acid-A receptor complex. It would promote sleep by specifically targeting the alerting signal in the suprachiasmatic nucleus, allowing the homeostatic mechanism to produce sleep.
Ramelteon is under global development by Takeda Pharmaceuticals as a nonscheduled sleep agent for the treatment of difficulty with sleep initiation, and is marketed under the brand name of Rozerem™ in the United States. In vitro, ramelteon demonstrates affinity and selectivity for human melatonin MT1 and MT2 receptors compared to melatonin. It also demonstrates full agonist activity in cells expressing human MT1 or MT2 receptors relative to melatonin.
In the European Union, Takeda is seeking marketing approval for the long-term treatment of transient and chronic insomnia as characterized by difficulty with sleep onset. Because most of the European clinical studies to date have used the 8 mg dose, the aim of this study is to assess the safety and efficacy of 4mg of ramelteon in a larger number of adults with chronic insomnia.
Subjects participating in this study will be required to report to a sleep laboratory and have polysomnography recordings over two consecutive nights for three sittings during a five week period. The total duration of the study is approximately 10 weeks.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Ramelteon 4 mg QD | Experimental | Drug: Ramelteon |
| Placebo QD | Placebo comparator | Drug: Placebo |
Who may qualify
- Ages
- 18 to 64 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (20 listed)
- A female subject of childbearing potential who is sexually active agrees to use adequate contraception from Screening throughout the duration of the study.
- Has a body mass index between 18 and 34, inclusive.
- Based on sleep history, the subject has had chronic insomnia for at least 3 months, as defined by the following:
- Based on sleep history, the subject reports a history of subjective sleep latency ≥45 minutes and a subjective total sleep time ≤6.5 hours for at least 3 months.
- Based on sleep history, the subject's habitual bedtime is between 10:00 PM and 1:00 AM.
Key exclusion criteria (43 listed)
- Has a known hypersensitivity to ramelteon or related compounds, including melatonin.
- Has participated in a study involving ramelteon within 6 months of initial Screening Visit.
- Has participated in any other investigational study and/or taken any investigational drug within 30 days or 5 half-lives (whichever is longer) prior to the first night of single-blind study medication.
- Has sleep schedule changes required by employment (eg, shift worker) within 3 months prior to the first night of single-blind study medication, or has flown across greater than 3 time zones within 7 days prior to Screening.
- Has participated in a weight loss program or has substantially altered his or her exercise routine within 30 days prior to the first night of single-blind study medication.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RamelteonAlso: Rozerem™, TAK-375Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks. | Drug | Ramelteon 4 mg QD |
| PlaceboRamelteon placebo-matching tablets, orally, once daily for up to 5 weeks. | Drug | Placebo QD |
Primary outcome
Mean Latency to Persistent Sleep Via Polysomnography (Nights 1-2).
Time frame: Nights 1-2
Elapsed time from the beginning of the Polysomnography recording to the onset of the first 10 minutes of continuous sleep was measured over 2 nights and the average time to sleep was calculated.
44 secondary outcomes
Mean Latency to Persistent Sleep Via Polysomnography (Nights 15-16).
Time frame: Nights 15-16
Mean Latency to Persistent Sleep Via Polysomnography (Nights 29-30).
Time frame: Nights 29-30
Subjective Sleep Latency, Per Post-sleep Questionnaire (Nights 1-2).
Time frame: Nights 1-2
Subjective Sleep Latency, Per Post-sleep Questionnaire (Nights 15-16).
Time frame: Nights 15-16
Subjective Sleep Latency, Per Post-sleep Questionnaire (Nights 29-30).
Time frame: Nights 29-30
Subjective Sleep Latency, Per Post-sleep Questionnaire (Week 2).
Time frame: Week 2
Subjective Sleep Latency, Per Post-sleep Questionnaire (Week 4).
Time frame: Week 4
Subjective Sleep Latency, Per Post-sleep Questionnaire (Week 5).
Time frame: Week 5
Total Sleep Time, Per Polysomnography (Nights 1-2).
Time frame: Nights 1-2
Total Sleep Time, Per Polysomnography (Nights 15-16).
Time frame: Nights 15-16
Total Sleep Time, Per Polysomnography (Nights 29-30).
Time frame: Nights 29-30
Subjective Total Sleep Time, Per Post-sleep Questionnaire (Nights 1-2).
Time frame: Nights 1-2
Subjective Total Sleep Time, Per Post-sleep Questionnaire (Nights 15-16).
Time frame: Nights 15-16
Subjective Total Sleep Time, Per Post-sleep Questionnaire (Nights 29-30).
Time frame: Nights 29 -30
Subjective Total Sleep Time, Per Post-sleep Questionnaire (Week 2).
Time frame: Week 2
Subjective Total Sleep Time, Per Post-sleep Questionnaire (Week 4).
Time frame: Week 4
Subjective Total Sleep Time, Per Post-sleep Questionnaire (Week 5).
Time frame: Week 5
Sleep Efficiency, Per Polysomnography (Nights 1-2).
Time frame: Nights 1-2
Sleep Efficiency, Per Polysomnography (Nights 15-16).
Time frame: Nights 15-16
Sleep Efficiency, Per Polysomnography (Nights 29-30).
Time frame: Nights 29-30
Subjective Sleep Quality, Per Post-sleep Questionnaire (Nights 1-2).
Time frame: Nights 1-2
Subjective Sleep Quality, Per Post-sleep Questionnaire (Nights 15-16).
Time frame: Nights 15-16
Subjective Sleep Quality, Per Post-sleep Questionnaire (Nights 29-30).
Time frame: Nights 29-30
Subjective Sleep Quality, Per Post-sleep Questionnaire (Week 2).
Time frame: Week 2
Subjective Sleep Quality, Per Post-sleep Questionnaire (Week 4).
Time frame: Week 4
Subjective Sleep Quality, Per Post-sleep Questionnaire (Week 5).
Time frame: Week 5
Wake Time After Sleep Onset, Per Polysomnography (Nights 1-2).
Time frame: Nights 1-2
Wake Time After Sleep Onset, Per Polysomnography (Nights 15-16).
Time frame: Nights 15-16
Wake Time After Sleep Onset, Per Polysomnography (Nights 29-30).
Time frame: Nights 29-30
Subjective Wake Time After Sleep Onset, Per Post-sleep Questionnaire (Nights 1-2).
Time frame: Nights 1-2
Subjective Wake Time After Sleep Onset, Per Post-sleep Questionnaire (Nights 15-16).
Time frame: Nights 15-16
Subjective Wake Time After Sleep Onset, Per Post-sleep Questionnaire (Nights 29-30).
Time frame: Nights 29-30
Subjective Wake Time After Sleep Onset, Per Post-sleep Questionnaire (Week 2).
Time frame: Week 2
Subjective Wake Time After Sleep Onset, Per Post-sleep Questionnaire (Week 4).
Time frame: Week 4
Subjective Wake Time After Sleep Onset, Per Post-sleep Questionnaire (Week 5).
Time frame: Week 5
Number of Awakenings After Persistent Sleep, Per Polysomnography (Nights 1-2).
Time frame: Nights 1-2
Number of Awakenings After Persistent Sleep, Per Polysomnography (Nights 15-16).
Time frame: Nights 15-16
Number of Awakenings After Persistent Sleep, Per Polysomnography (Nights 29-30).
Time frame: Nights 29-30
Subjective Number of Awakenings, Per Post-sleep Questionnaire (Nights 1-2).
Time frame: Nights 1-2
Subjective Number of Awakenings, Per Post-sleep Questionnaire (Nights 15-16).
Time frame: Nights 15-16
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jun 2010.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Rozerem Package Insert.Link provided by the sponsor.
Related trials for Sleep Initiation and Maintenance Disorders
Recruiting
Addressing Nocturia in Older Women Utilizing Behavioral Sleep Intervention and Brief Mindfulness
Nocturia, Insomnia
Not yet recruiting
A Transdiagnostic Sleep Health Intervention for Veterans With PTSD
Stress Disorders, Post-Traumatic, Sleep Initiation and Maintenance Disorders
Recruiting
Effect of Cyclic Sighing Breathing Exercise on CRBD, Pain, and Sleep Quality in Patients Undergoing TUR
Transurethral Resection of Bladder Tumor, Transurethral Resection of the Prostate (TURP)
Recruiting
Treating Insomnia in Mild Cognitive Impairment
Mild Cognitive Impairment (MCI), Insomnia
RecruitingPhase 4
The Effects of Orexin Antagonism on Fear Extinction in PTSD
Insomnia, PTSD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Medical Director Clinical Science study director
Takeda
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Ramelteon in people with Sleep Initiation and Maintenance Disorders, run by Takeda.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 20 inclusion and 43 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Jun 2010. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 5 Nov 2009). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean Latency to Persistent Sleep Via Polysomnography (Nights 1-2). (time frame: Nights 1-2). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jun 2010.